Abstract
Developments in the field of adenosine receptor (AR) agonists of the past years are presented and discussed. Four different AR subtypes, A1, A2A, A2B, and A3, have been cloned from different species including the human receptors. Recombinant ARs expressed in permanent mammalian cell lines have found wide application in the screening of new ligands. Considerable differences are observed among data from different laboratories, using recombinant receptors for the assays. Reevaluation of compounds at all four receptor subtypes has shown that agonists that were believed to be selective for either A1 or A2A ARs may be potent A3 agonists and thus, nonselective. Potent and selective agonists for two of the AR subtypes, A1 and A3, have been developed. Truly selective A2A AR agonists, however, are presently not available. Potent or selective A2B agonists are still lacking. Since the treatment with AR agonists may lead to fast desensitization of the receptors, partial agonists, and indirect AR agonists, such as adenosine kinase inhibitors, or allosteric enhancers of adenosine binding, are being developed as site- and event-specific agents.
Current Medicinal Chemistry
Title: Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Volume: 7 Issue: 12
Author(s): C. E. Muller
Affiliation:
Abstract: Developments in the field of adenosine receptor (AR) agonists of the past years are presented and discussed. Four different AR subtypes, A1, A2A, A2B, and A3, have been cloned from different species including the human receptors. Recombinant ARs expressed in permanent mammalian cell lines have found wide application in the screening of new ligands. Considerable differences are observed among data from different laboratories, using recombinant receptors for the assays. Reevaluation of compounds at all four receptor subtypes has shown that agonists that were believed to be selective for either A1 or A2A ARs may be potent A3 agonists and thus, nonselective. Potent and selective agonists for two of the AR subtypes, A1 and A3, have been developed. Truly selective A2A AR agonists, however, are presently not available. Potent or selective A2B agonists are still lacking. Since the treatment with AR agonists may lead to fast desensitization of the receptors, partial agonists, and indirect AR agonists, such as adenosine kinase inhibitors, or allosteric enhancers of adenosine binding, are being developed as site- and event-specific agents.
Export Options
About this article
Cite this article as:
Muller E. C., Adenosine Receptor Ligands-Recent Developments Part I. Agonists, Current Medicinal Chemistry 2000; 7 (12) . https://dx.doi.org/10.2174/0929867003374101
DOI https://dx.doi.org/10.2174/0929867003374101 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti Diabetic Effect of Cherries in Alloxan Induced Diabetic Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research
Drug Metabolism Letters Mediterranean Diet and the Metabolic Syndrome: The Role of Protein
Current Nutrition & Food Science Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Current Topics in Medicinal Chemistry Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Left Ventricular Noncompaction: New Insights into a Poorly Understood Disease
Current Cardiology Reviews